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Positive and negative nano-electrospray mass spectrometry of 
ruthenated serum albumin supported by docking studies: an 
integrated approach towards defining metallodrug binding sites 
on proteins 
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a
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b
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a
, Miloš K. Milčić
d
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Binding of three ruthenium(II) compounds of general formula mer-[Ru(L3)(N-N)X][Y] (where L3 = 4′-chloro-2,2′:6′,2″-
terpyridine (Cl-tpy); N-N = 1,2-diaminoethane (en), 1,2-diaminocyclohexane (dach) or 2,2′-bipyridine (bipy); X = Cl; Y = Cl) 
to human serum albumin (HSA) has been investigated by nano-LC/nano-ESI MS and docking studies. Bottom-up 
proteomics approach has been applied for structural characterization of metallated protein and the data were analyzed in 
both,  positive and negative ion mode. The negative ion mode has been achieved after post-column addition of 
isopropanol solution of formaldehyde that enabled sample ionization under micro-flow rates. Negative ion mode MS have 
proved to be beneficial for the analysis of binding sites on ruthenated protein in terms of ion charge reduction and 
consequent simplification of target sequence identification based on isotopic differences between ruthenated and non-
ruthenated peptides. Moreover, negative ion mode ESI MS shows the advantage of singly charged ion formation and, 
unlike MALDI MS, does not cause complete ligand fragmentation, merging the benefits of each method into a single 
experiment. Six target sequences were identified for the binding of en and dach compounds, and four sequences for the 
binding of bipy. All compounds have been found to bind histidine and one aspartate residue. Docking studies showed that 
the identified sequences are constituents of five distinct binding sites for en and dach, or two sites for bipy complex. The 
selection of binding sites seems to be dependent on chelate ligand and on form of the complex prior or after hydrolysis of 
leaving chloride ligand.
  
Significance to metallomics 
Improving mass spectrometry-based analytical methodology for structural characterization of metallodrug-protein interaction has become an important 
goal in the field of bioinorganic chemistry. Here, we introduce negative ion mode nano-LC/nano-ESI MS as a tool for determination of binding sites of three 
Ru(II) compounds on human serum albumin. Complemented with positive ion mode and docking studies, MS- analysis showed distinct advantages over 
existing methodology. The results revealed effects of chelate and leaving ligands on binding site selection. 
 
Introduction 
 
Low selectivity, severe toxicity and acquired resistance of platinum 
drugs prompted the development of novel metal-based 
chemotherapeutics. Ruthenium compounds have emerged as 
promising candidates due to their low toxicity, increased selectivity 
towards cancer cells and pronounced antimetastatic effect1–3. 
Consequent growing interest in ruthenium-based compounds has 
shifted the spotlight from DNA to proteins as potential 
biomolecular targets responsible for anticancer activity of these 
drugs4.  
Mass spectrometry (MS) has drawn considerable interest as a tool 
 for structural characterization of metallodrug-protein interactions 
due to its accuracy, short analysis time and low sample 
consumption5,6. Further, transition metals such as Pt or Ru have 
distinct isotopic distributions that are not naturally encountered in 
biological samples, which facilitates targeted analysis and justifies 
the choice of MS methods for this application. Among soft 
ionization MS techniques, matrix-assisted laser desorption 
ionization (MALDI) and electrospray ionization (ESI) are most often 
employed for characterization of metallodrug-protein interactions. 
Although singly charged ion formation is a significant advantage of 
MALDI MS in terms of facile identification of metallated peptides 
based on isotopic differences, it is not so commonly used due to in-
source fragmentation of coordinated metal compounds7. 
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Electrospray ionization  proved to be more suitable for this purpose 
because the protein-bound compounds largely remain intact during 
the process of ionization7. Further, the ease of hyphenation of ESI 
MS to liquid chromatography (LC) and other separation techniques, 
makes it more convenient for direct analysis of peptides in a typical 
bottom-up proteomics approach. The main disadvantage of ESI is 
multiple charging that can aggravate identification of metallated 
peptides because it is challenging to differentiate between isotopic 
distributions of modified and larger non-modified peptides. Further, 
multiple charge state distributions can lead to isobaric interferences 
and mass spectral congestion in complex samples. Consequently, 
ESI MS-based data describing metallodrugs’ binding sites on larger, 
biologically relevant proteins and cellular targets is scarce8,9.  
In this work, we have used nano-LC/nano-ESI MS for determination 
of binding sequences and target amino acids for the binding of 
three ruthenium compounds of general formula mer-[Ru(L3)(N-
N)X][Y]  (where L3 = 4′-chloro-2,2′:6′,2″-terpyridine(Cl-tpy); N-N = 
1,2-diaminoethane (en), 1,2-diaminocyclohexane (dach) or 2,2′-
bipyridine (bipy); X = Cl; Y = Cl)10 (Fig. 1), to human serum albumin 
(HSA). The selected highly water-soluble Ru compounds proved to 
be moderately cytotoxic towards several cancer cell lines and 
showed strong binding to both, DNA and proteins10,11. Human 
serum albumin is the main protein responsible for drug transport 
and uptake, but is also considered to be the key for anticancer 
activity of several Ru drug candidates. Clinically relevant KP1019 
and its sodium salt analogue NKP-1339 are believed to exhibit 
tumor selectivity trough HSA-mediated pathway that is based on 
enhanced permeability and retention (EPR) effect of tumor 
tissues12. The EPR effect is attributed to defective architecture of 
tumor blood vessels that allows macromolecules (>40 kDa) such as 
HSA-drug complex to transit trough gaps in endothelial cells of 
blood vessels and  accumulate in tumor tissue13.  
 
 
Fig. 1. Structural formula of [Ru(Cl-tpy)(en)Cl]+ (1), [Ru(Cl-tpy)(dach)Cl]+ (2) and [Ru(Cl-
tpy)(bipy)Cl]+ (3). 
 
 
So far, MS-based analysis of metallodrug binding to proteins has 
been performed almost exclusively in the positive ion mode, while 
the negative ion mode has been rarely applied.14,15 This study 
describes identification of HSA binding sites  for selected Ru 
compounds in both, positive and negative ion modes and discusses 
the advantages of each approach, as well as  their complementarity 
and suitability for wider applications. Further, docking studies have 
been used to complement and rationalize the obtained 
experimental data. 
Experimental 
 
General procedures 
Angiotensin II and HSA, purchased from Sigma-Aldrich (St. Louis, 
MO, USA), were dissolved in 25 mM sodium bicarbonate buffer of 
pH 7.8 to a concentration of 1 mg/mL. Angiotensin II was mixed 
with 5 µL of each complex solution, obtained after dissolving a small 
amount of [Ru(4’-Cl-tpy)(en)Cl]+ (1), [Ru(4’-Cl-tpy)(dach)Cl]+ (2) and 
[Ru(4’-Cl-tpy)(bipy)Cl]+ (3)10,11 in miliQ water, and diluted to a final 
concentration of 0.1 mg/mL. After 3h of incubation at 37 ̊ C, each 
Ru-bound peptide was purified using ZipTip C18 column 
(Eppendorf, Hamburg, Germany). Human serum albumin was mixed 
with each Ru compound in 1:10 molar ratio, diluted to 0.1 mg/mL 
concentration and incubated for 24 h at 37   ̊C. After the incubation, 
unbound complexes were removed upon extensive ultrafiltration 
using Centricon ultrafiltration units (10 kDa cut off; Millipore Co.). 
The remaining HSA-Ru adducts were diluted to a starting 
concentration and subjected to trypsin (Merck, Germany)  digestion 
(5 µL of 1 mg/mL trypsin) at 37  ̊C for 18 h. Both, angiotensin and 
HSA tryptic digest were dried in centrifugal vacuum evaporator 
(Eppendorf) and resuspended in 0.1% formic acid (Kemika, Zagreb, 
Croatia) to a 0.1 mg/mL concentration prior to MS measurements. 
Acetonitrile used for LC mobile phase preparation, formaldehyde 
and isopropanol used for negative ion mode enhancement, as well 
as leucine enkephaline used as a reference material for MS 
calibration were all purchased from Sigma-Aldrich. 
LC/MS conditions 
The obtained HSA peptides were resolved on nanoACQUITY UPLC 
(Waters, Milford, MA, USA), equipped with nanoACQUITY UPLC 2G-
V/M Symmetry C18 Trap Column (100Å, 5μm, 180 μm x 20 mm) and 
ACQUITY UPLC BEH130 C18 Analytical Column (130 Å, 1.7 μm, 100 
μm × 100 mm). The injection volume was 4 µL and column 
temperature 40 ̊ C. Isocratic delivery of mobile phase A (0.1 % 
formic acid) to the trap column was performed at 15 µL/min for 2 
min. Elution of the peptides was performed using a gradient of 
mobile phase B (0.1% formic acid in 95% acetonitrile) from 0.1% to 
99% in 30 min, at 1 µL/min flow rate. Mass spectrometry 
measurements were performed on SYNAPT G2-Si mass 
spectrometer (Waters, Milford, MA, USA). Capillary and cone 
voltages were set to 3.5 kV and 40V, respectively. Source 
temperature was 80 ̊ C and nanoflow gas pressure 1 bar. Post-
column addition of 0.1% formaldehyde in isopropanol was 
performed at a flow rate of 0.4 µL/min. The data was recorded in 
positive and negative MSE resolution mode16,17, covering a mass 
range between 50 and 4000 Da. Collision cell energy was 
alternating between low energy (4 eV) to collect peptide precursor 
(MS) data, and elevated energy (ramping from 20 to 40 eV) to 
obtain peptide fragmentation (MSE) data. The lock spray (1 ng/μL 
leucine enkephalin in 50:50 IPA/0.1% formic acid) was introduced 
every 1 min to ensure high mass accuracy. 
The positive ion mode data was processed using PLGS software 
(PLGS; v 3.0.1, Waters). Database containing HSA sequence was 
created and the data were searched with trypsin as a digestion 
reagent, with two potential miscleavages. Peptide and fragment 
tolerance were set to automatic. Apart from oxidation M and 
dehydration ST, monoisotopic mass of each [Ru(Cl-tpy)(chel)]2+ 
complex  was set as variable side chain modification in 
corresponding data set. Two mass units were substracted from 
each complex mass, to compensate for twofold charge of the 
complexes. 
MALDI MS/MS measurements were performed as described 
previously11.  
 
Computational studies 
Page 2 of 11Metallomics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
M
et
al
lo
m
ic
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
01
 M
ar
ch
 2
01
8.
 D
ow
nl
oa
de
d 
by
 F
re
ie
 U
ni
ve
rs
ita
et
 B
er
lin
 o
n 
03
/0
3/
20
18
 1
4:
09
:4
4.
 
View Article Online
DOI: 10.1039/C7MT00330G
Journal Name ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
The full geometry optimization of all ruthenium complexes were 
carried out with B3LYP hybrid functional using 6-31g** basis set for 
all non metal atoms and standard lanl2dz basis set for ruthenium 
atom (with effective core potential (ECP) for inner electrons). The 
harmonic vibrational frequencies were evaluated for each fully 
optimized structure at same level of theory to confirm the nature of 
the found minima and no imaginary frequencies were found. All 
quantum chemical calculations, needed to determine the 
equilibrium constants, were carried out using the GAUSSIAN09 
program package18. 
Crystal structures of human serum albumin (HSA, PDB code 
1BM019) for docking study was extracted from a Protein Data 
Bank20. The water molecules and all other ligand residues were 
removed from the structure. Optimized structures of metal 
complexes and structure of HSA protein were used for doking 
preparation in AutoDockTools program, while the docking study 
was done with AutoDock program21. All protein residues were kept 
rigid and all single ligand bonds were set to be rotational. A grid 
box, containing the whole protein, was used to accommodate the 
ligand to move freely during docking run.  
Results and discussion 
 
Binding of the complexes to angiotensin II 
In order to investigate the behavior of peptide-bound ruthenium 
compounds in positive and negative ESI mode, MS spectra were 
first recorded after the incubation of each compound with a model 
peptide, angiotensin II (Fig. S1). In the positive ion mode, formed 
ruthenated angiotensin is detected as a triply-charged ion in case of 
all three compounds. Upon Cl ligand hydrolysis and subsequent 
complex binding, the peptide is provided with extra positive charge 
originating from metal center and multiple charging is therefore 
favored. Negative ion mode spectra (Fig. S2) are acquired after 
post-column addition of formaldehyde dissolved in isopropanol, as 
a negative ion mode modifier. The application of negative ion mode 
modifiers, their mechanism of action and advantages of their use in 
nano-ESI MS analysis of peptides have been explained thoroughly in 
our recent paper22. The predominant species detected in all 
negative ion mode MS spectra are singly charged ions of ruthenated 
angiotensin, as well as their formic acid adducts. This can be 
explained with analytes’ intrinsic positive charge that prevents 
multiple charging in the negative ion mode. This approach can be 
observed as a way of ion charge reduction that accounts for 
significant method simplification. More precisely, the produced 
effect implies the obtaining of MALDI-like ESI MS spectra. In this 
way, the advantages of MALDI singly charged ion formation and ESI 
preservance of intact metallodrug-peptide/protein interactions are 
merged in a single experiment. 
 
Binding of the complexes to human serum albumin 
 
Positive ion mode 
In order to optimize nano-ESI MS-based approach for facilitated 
target sequence identification, MSE data were recorded in positive 
ion mode for each Ru compound-HSA tryptic digest resolved on 
reversed-phase nano-UPLC column. The above mentioned 
challenges of manual identification of target  sequences for binding 
of ruthenium have been addressed by setting each complex mass 
(without leaving Cl ligand) as an amino acid side chain modification 
and processing the obtained data using ProteinLynx Global Server 
(PLGS) software. Since MSE data includes low energy (LE) and high 
energy (HE) spectra of the analyzed samples, both, target 
sequences and target amino acids for each Ru compound could be 
identified from a single dataset. The identified target sequences are 
shown in LE MSE spectra (Fig. S3, S4 and S5 for compound 1, 2 and 
3, respectively). 
For compound 1 and 2 six target sequences were found (five using 
PLGS and one manually), while compound 3 showed lower binding 
affinity towards the protein with four target sequences detected. 
This is probably because, unlike en and dach, bipy ligand lacks the 
ability of strong hydrogen bond formation with the surrounding 
amino acid residues. Target amino acid residues were determined 
based on HE MSE spectra. The compounds 1 and 2 target four 
histidine (His) and one aspartate (Asp) residues, while compound 3 
targets two His and one Asp residues. An example of PLGS extracted 
HE MSE spectrum for the binding of 1 to His of 
146HPYFYAPELLFFAK159 HSA sequence is shown in Fig. S6. The list of 
all software identified fragment ions for the target sequences of the 
selected compound 2 is shown in Table S1. The target amino acid of 
the remaining 1DAHK4 sequence that was found manually will be 
discussed in the following section. We believe the herein described 
approach can also be used for identification of metallodrug target 
proteins in more complex samples, as previously described by Wills 
et al using a similar approach23,24. Further, the application of nano-
LC/nano-ESI MS system has advantages in terms of low sample 
consumption and increased sensitivity comparing to conventional 
ESI MS25. This can be of uttermost importance because relevant 
drug targets are often low abundance proteins and the amount of 
sample available for measurements is often limited. Nevertheless, 
precaution should be made when working with more complex 
samples and the obtained results should be checked for metal 
isotopic distribution of the obtained fragment ions, to minimise 
false positives23,24. Also, the fact that proteomics software packages 
do not take into account metal isotopic distribution should be 
considered, as omission can happen during data processing. Despite 
of the accentuated challenges, the described approach greatly 
facilitates binding sequences identification. 
 
Negative ion mode 
The ability of peptides and metallopeptides to ionize in the negative 
ion mode under micro- and nano-flow rates has been attributed to 
formaldehyde proton scavenging effect and electrospray stabilizing 
effect of isopropanol22. Post-column addition of formaldehyde does 
not affect chromatographic separation or positive ion mode 
ionization efficiency, so complementary set of data can be obtained 
without additional changes in instrumental setup except switched 
polarities. Therefore, obtaining comparable results in the negative 
ion mode would present a direct confirmation of the results 
obtained in the positive ion mode and vice versa. To achieve this, 
target sequences for the binding of the tested compounds were 
identified manually in the negative ion mode LE MSE spectra 
(Figures S7, S8 and S9 for compounds 1, 2 and 3, respectively). The 
identification was facilitated thanks to reduced multiple charging 
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and consequent significant isotopic differences between 
ruthenated and non-ruthenated peptides. Although the intensity of 
negative ions as well as the quality of the spectra decreases 
comparing to the positive ion mode (particularly with increasing 
m/z), negative ion mode proved to be sufficient for qualitative 
analysis. Moreover,  good complementarity with the positive ion 
mode data was obtained, e.i. the same six target sequences were 
identified using either approach. In order to illustrate similarity 
between negative ion mode ESI MS and positive ion mode MALDI 
MS analyses, the spectra of DAHK peptide adduct with compound 2 
are shown in Fig. 2. It can be seen that the detected ions are singly 
charged using either approach. Observable differences include 
complete loss of bidentate chelate ligand during MALDI analysis, 
while the chelate predominantly remains coordinated to ruthenium 
moiety during ESI process. This accounts for significant advantage 
of ESI MS, since no additional method is required to demonstrate 
that the loss of ligands is not due to solution hydrolysis, but MALDI 
in-source fragmentation11. 
 
Fig 2. Negative ion mode ESI MS (upper trace) and positive ion mode MALDI MS spectra 
(bottom trace) of DAHK sequence upon binding of [Ru(Cl-tpy)(dach)Cl]+ complex. 
 
 
Since the identity of DAHK target sequence was proposed solely 
based on mass shift and isotopic distribution, no information about 
target amino acid was obtained. For that reason, tandem mass 
analysis was performed in negative ESI mode. The obtained 
spectrum is compared to MALDI MS/MS spectrum in positive ion 
mode (Fig. 3). Unlike MS, MS/MS analysis in negative ESI mode 
leads to bidentate ligand fragmentation, as noted during MALDI 
analysis. All detected fragment ions in both spectra are singly 
charged, but they differ in between. It can be noted that mostly y-
series ions are formed during ESI analysis while MALDI 
predominantly produces a and b ion series. The presence of 
ruthenated y2 and x2 ions in ESI, or b3 and a3 ions in MALDI 
spectrum indicates the binding of the compound to His3. The 
observed fragmentation type differences point out methodological 
complementarity.  
 
Fig 3. Negative ion mode ESI MS/MS (upper trace) and positive ion mode MALDI 
MS/MS (bottom trace) spectra of  DAHK sequence adduct with compound [Ru(Cl-
tpy)(dach)Cl]
+
. 
  
*indicates [Ru(Cl-tpy)]
2+
 fragment.
 
In this study, negative ion mode ESI MS was used as a tool for 
determination of metallodrug binding sites on proteins. Moreover, 
we believe the herein applied method for negative ionization 
enhancement can also be used for simultaneous detection of 
metallodrug binding in a mixture of biomolecules. Separation and 
simultaneous MS detection of adducts formed between 
metallodrug and oligonucleotide or protein has been recently 
shown using capillary zone electrophoresis coupled to ESI MS26. In 
this study, oligonucleotide metallation was resolved at a single 
nucleotide level. The spectra could be obtained only in the positive 
ion mode, because the negative charge of the nucleotide fragments 
is cancelled due to positive charge of the attached metal 
compound, which prevented negative ionization. Here, we have 
shown that, under the same operating conditions (except switched 
polarities), negative ionization of metallated peptides can be 
achieved, despite intrinsic positive charge of the analyte. Therefore, 
we believe the same could apply for e.g. metallodrug-
(oligo)nucleotide binding investigation, which accentuates the 
potential of the presented approach to be used for wider 
applications than presented herein. 
 
Docking studies 
In order to rationalize the experimentally obtained data, docking 
studies have been performed. The investigated complexes are 
known to bind proteins after Cl ligand exchange, followed by 
aquation and subsequent coordination to electron-donor amino 
acid residues10,11. Aquation rate proved to be dependent on the 
nature of chelate ligands in chloride containing complexes and is 
linked to drugs’ cytotoxic effect27. Since blood chloride 
concentration is relatively high (104 mM), the hydrolysis is mostly 
supressed and the complexes are in their less reactive chloro form. 
Chloride concentration desreases in cytoplasm (23 mM) and 
nucleus (4 mM), which favors formation of more reactive aqua 
species28. Aqua species are easily deprotonated, leading to hydroxo 
species formation. Although the predominance of the named 
species depends on the location of the complex (or experimental 
conditions), all of them (chloro-, aqua- or hydroxo-) are present in 
solution and are, therefore, included in docking studies. Based on 
the obtained MS results and spatial localization of the identified 
target sequences, it can be concluded that there are three HSA 
regions for the binding of the tested Ru compounds (Fig. S10) and 
only one of them belongs to major HSA drug binding sites. The first 
one is located at domain I, in close proximity to 
146HPYFYAPELLFFAK159 sequence. The second one is located 
between subdomains IA and IIA, occupying the space between 
1DAHK4, 5SEVAHR10 and 65SLHTLFGDK73 sequences. The third binding 
region is located at IIB subdomain, between 324DVFLGMFLYEYAR336 
and 146HPDYSVVLLLR159 sequences. During data interpretation, 
previously determined average number of bound complex 
molecules per protein (seven for compound 1, nine for 2 and two 
for complex 3) was taken into account29. The illustration of binding 
sites for each complex chloro-, aqua- and hydroxo- form is shown in 
Fig. S11 , while their respective binding energies are listed in Table 
S3. The obtained values indicate that chloro- complexes bind 
somewhat stronger when compared to hydroxo- species. Binding 
affinities are, in case of both, chloro- and hydroxo- complexes, 
highest  in case of compound 2, while compound 3 shows the 
lowest  binding affinities. It is worth mentioning that AutoDock 
program has a standard deviation of about 2-3 kcal/mol for the free 
energy prediction30, which is not sufficient to provide confident 
affinities of sites for binding of certain form of the complexes (in 
this case the tested solution is a mixture of chloro, aqua-, and 
hydroxo-form of complex 1, 2, or 3), but some trend can be 
observed. As the chloro, aqua-, and hydroxo- forms do not bind to 
the same binding site on the protein, the exact values of binding 
energy are not necessary. The lowest number of binding sites was 
obtained for aqua species that were found to predominantely 
interact with surface amino acid residues. None of aqua complex 
binding sites correspond to MS-determined target sequences. By 
comparing all theoretically predicted binding sites with MS-
obtained sequences, it can be concluded that there are five sites on 
HSA for binding of compounds 1 and 2, and two sites for binding of 
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compound 3. The location of the binding sites with respect to MS-
identified sequences is shown in Fig. 4. , while their binding 
energies, MS-identified target amino acids and forms in which the 
complexes bind to each site are accentuated in Table S4.  
 
Fig 4. HSA binding sites for [Ru(Cl-tpy)(en)Cl]+ (1), [Ru(Cl-tpy)(dach)Cl]+ (2) and [Ru(Cl-
tpy)(bipy)Cl]+ (3), obtained by docking studies. Chloro forms of the complexes are 
shown green, while hydroxo are red. MS-identified sequences are shown black. 
 
According to the docking studies, all complexes show the highest 
affinity for the binding of the protein region located between IA and 
IIA subdomains, which includes 1DAHK4, 5SEVAHR10 and 
65SLHTLFGDK73 sequences. There are two sites in this region for the 
binding of compounds 1 and 2, and one site for the binding of 3.  
The 1DAHK4 sequence that is one of the constituents of this binding 
site is known as a hallmark of albumin metal binding31,32. It 
comprises the N-terminal site (NTS) for binding of metals, mainly 
through coordination with His3 that is also found to be the target 
for the binding of 1, 2 and 3. About 2% of NTS of HSA is populated 
with Cu(II) and it makes HSA the second largest pool of cooper in 
human blood serum32. Another sequence that is a part of the 
second binding site in this protein region is 65SLHTLFGDK73. This 
sequence contains His67 whose imidazole nitrogen is a ligand for 
binding of various metals, and is described in literature as HSA 
metal binding site A32. Also, His67 together with His9 from 
5SEVAHR10 sequence has been identified as cisplatin binding site on 
HSA33,34. 
 
Table 1. Binding energies and target amino acids for coordination of investigated Ru(II) 
complexes 1, 2 and 3 on HSA. 
The binding region that encompasses 146HPYFYAPELLFFAK159 
sequence is located at the lower entrance to subdomain IB, 
consisted mainly of three α-helices that form hydrophobic groove. 
As shown by MS data, ruthenium center from each compound binds 
to imidazole nitrogen of His146. This amino acid has also been 
recently confirmed to be the target of KP1910, based on X-ray 
data12. 
The third binding region is located between IA and IIA subdomains 
and is consisted of 324DVFLGMFLYEYAR336 i 338HPDYSVVLLLR348 
sequences. Compounds 1 and 2 both coordinate His338 and 
Asp324, while compound 3 only binds to Asp324. Monodentate 
binding of Ru compounds trough coordination of O atoms from Asp 
residues of various proteins have been reported before35. 
One interesting observation is that no Cys binding of the complexes 
has been identified. Human serum albumin contains one free Cys34 
residue, that is often identified as a target for binding of various 
transition metal drugs6. Although binding of both, Ru(III) and Ru(II) 
drugs to Cys moiety has been reported36–38, the ability of Ru 
complex to reach Cys34 of HSA seems to be ligand depended39. 
Namely, Cys34 residue is placed within a crevice of the protein that 
is not easily accessible to complexes that contain large ligands, due 
to steric hindrance. In the study describing Ru(II) arene compound 
binding to HSA, it has been demonstrated that biphenyl containing 
compound can not bind to Cys34, unlike p-cymene containing 
compound that is readily bound to Cys moiety39. Although expected 
as a potential target, Cys34 complex binding has not been identified 
in this study, due to the nature of large Cl-tpy ligand that prevents 
drug entrance into the protein crevice, as confirmed by docking 
studies (data not shown). 
 
Conclusions 
Here, we have described nano-LC/nano-ESI MS-based approach for 
identification of binding sites of three Ru coordination compounds 
of general formula [Ru(Cl-tpy)(chel)Cl]Cl on human serum albumin. 
This study introduces negative ion mode mass spectrometry as a 
tool for investigating interactions between transition metal 
compounds and proteins, with a potential for wider applications. 
Although positive ion mode MSE approach enabled simultaneous, 
automatic identification of target sequences and target amino acids 
for the binding of the tested compounds, negative ion mode 
approach has shown distinct advantage of singly charged ion 
formation that significantly reduces the complexity of manual data 
interpretation. Performed analyses in both ion modes provide good 
reliability of the obtained data that includes six target HSA 
sequences for the binding of 1 and 2, and four sequences for the 
binding of compound 3. As shown by docking studies, the identified 
sequences are constituents of five distinct binding sites for 1 and 2, 
or two sites for compound 3. The choice of the binding site seems 
to be dependent on the form of the complex (chloro-, hydroxo- or 
aqua-). The strongest  binding  of the complexes were obtained  for 
their chloro- form. Although Cl ligand hydrolysis suppression in 
blood is considered as a way of reduction of drugs’ side reactivity, it 
is known that the largest portion of complexes end up bound to 
serum proteins40 after intravenous administration and the obtained 
results offer an explanation. Finally, since identified target amino 
acid residues, His and Asp, are often implicated in catalytic 
processes, the obtained results also suggest the potential of the 
tested Ru compounds to alter catalytic activity of enzymes which 
could be relevant for their mode of action. 
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Figure 1.  
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Figure 2.  
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Figure 3.  
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Figure 4.  
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Table 1. Binding energies and target amino acids for coordination of investigated Ru(II) 
complexes 1, 2 and 3 on HSA. 
 
Binding 
site 
 
Binding energy (kcal/mol) 
 
1 
 
2 
 
3 
1 
-8,12 
[RuCl(4’-Cl-tpy)(en)]
+
 
His67, His3 
-9,14 
[RuCl(4’-Cl-tpy)(dach)]
+ 
His67, His3 
-6,98 
[RuCl(4’-Cl-tpy)(bipy)]
+ 
His9,His3,His67 
2 
-7.80 
 [RuOH(4’-Cl-py)(en)]
+ 
His146 
-8,38 
[RuOH(4’-Cl-tpy)(dach)]
+ 
His9 
-5,84 
[RuOH(4’-Cl-tpy)(bipy)]
+ 
Asp324 
3 
-7,09 
[RuCl(4’-Cl-tpy)(en)]
+
 
His338 
-8,37 
[RuOH(4’-Cl-tpy)(dach)]
+ 
Asp324 
- 
4 
-6,83 
[RuCl(4’-Cl-tpy)(en)]
+
 
His9 
-6,48 
[RuOH(4’-Cl-tpy)(dach)]
+ 
His338 
- 
5 
-5,84 
[RuOH(4’-Cl-tpy)(en)]
+ 
Asp324 
-6,47 
[RuOH(4’-Cl-tpy)(dach)]
+ 
His146 
- 
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